Gilead Sciences | Der Umsatz



Sales Veränderung Datum
AbbVie USD 13.34B 1.76B 2025-03
Agios Pharmaceuticals USD 10.73M 1.77M 2024-12
ALKERMES USD 430M 51.9M 2024-12
Alnylam Pharmaceuticals USD 593.17M 92.25M 2024-12
Amgen USD 9.09B 583M 2024-12
Biogen USD 2.45B 11.1M 2024-12
BioMarin Pharmaceutical USD 747.31M 1.57M 2024-12
Bristol-Myers Squibb USD 11.2B 1.14B 2025-03
Eli Lilly USD 13.53B 2.09B 2024-12
Gilead Sciences USD 6.67B 899M 2025-03
GlaxoSmithKline GBP 8.12B 108M 2024-12
Glaxosmithkline GBP 8.12B 105M 2024-12
Incyte USD 1.18B 40.83M 2024-12
J&J USD 21.89B 630M 2025-03
Merck USD 15.53B 94M 2025-03
Moderna USD 966M 896M 2024-12
Neurocrine Biosciences USD 627.7M 5.6M 2024-12
Novartis USD 13.15B 330M 2024-12
Pfizer USD 17.76B 61M 2024-12
PTC Therapeutics USD 213.17M 16.39M 2024-12
Regeneron Pharmaceuticals USD 3.79B 70M 2024-12
Sanofi EUR 9.9B 660M 2025-03
Sarepta Therapeutics USD 658.41M 191.24M 2024-12
United Therapeutics USD 735.9M 13M 2024-12
Vertex Pharmaceuticals USD 2.91B 140.1M 2024-12



Gilead Sciences Der Umsatz - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Apr 2025.